U.S. market Open. Closes in 40 minutes

IMTXW | immatics biotechnologies GmbH Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 0.4575 - 0.4600
52 Week Range 0.4575 - 0.4600
Beta N/A
Implied Volatility N/A
IV Rank N/A
Day's Volume 1
Average Volume N/A
Shares Outstanding 2,023,861,023
Market Cap 930,976,071
Sector Healthcare
Industry Biotechnology
IPO Date 2020-07-02
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS N/A
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 542
Country USA
Website IMTXW
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401, which is in Phase 1b clinical trial; and IMA402 and IMA403, which are in preclinical stages. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
IMTXW's peers: BCYC, ATNFW, ARTLW, BCDAW, IMACW, ENTXW, LEXXW, BCTXW
*Chart delayed
Analyzing fundamentals for IMTXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see IMTXW Fundamentals page.

Watching at IMTXW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IMTXW Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙